


CRAN-Related NCI Activities and Research Priorities

William Klein, Ph.D.
Associate Director
Behavioral Research Program
Division of Cancer Control and Population Sciences

May 11, 2022

DCCPS Organizational Leadership



Outline

- Tobacco Control Research and Impact
- Alcohol Research Initiatives
- Cannabis Research Initiatives
- American Indian/Alaska Native (AI/AN)-Specific Initiatives
- Funding
- Data Collection

Tobacco Control Research and Impact

Portfolio Overview



**>100
Grants**




**>\$54M direct
funding**

Disclaimer: Findings based on unpublished NCI data


TCRB Portfolio FY 2021:

Grants by Type of Research (Primary)



TCRB Portfolio FY 2021:

Grants by Tobacco Type – Multiple vs. Single Product Focus





*[Electronic Nicotine Delivery Systems](#)

Disclaimer: Findings based on unpublished NCI data

TCRB Portfolio FY 2021:

Grants by Priority Population



Grants could be coded for more than one priority population
Disclaimer: Findings based on unpublished NCI data

Cancer Center Cessation Initiative (C3I)

C3I Goal: Enhance capacity of cancer centers to address tobacco cessation with cancer patients

C3I Funding:

- 21st Century Cures Act in 2016, \$1.8 billion for the Cancer Moonshot over 7 years
- Supplements to P30 Cancer Center Support Grants (CCSG)
- Coordinating Center at the University of Wisconsin
- 52 cancer centers were funded (1-3 years each)



Cancer Center Cessation Initiative (C3I)

Funded centers are expected to:


- Take a *population-based approach* –
 - Tobacco use status is assessed and documented for every cancer center patient
 - Deliver cessation treatment to every patient who uses tobacco (motivational treatments for those not willing to make a quit attempt)
 - Use the electronic health record to create and use a tobacco user registry
- Commit to sustaining the program

Coming Soon!

- Provides cancer care clinicians with the latest knowledge concerning smoking cessation treatment among their patients
- Provides scientists with descriptions of research gaps to be filled
- Scientific editorial committee:
 - Timothy Baker, PhD
 - Michael Fiore, MD, MPH, MBA
 - Anne Joseph, MD, MPH
 - Monica Webb Hooper, PhD
 - Gordon Willis, PhD
- Anticipated publication: June 2022



NATIONAL CANCER INSTITUTE



NCI TOBACCO CONTROL
MONOGRAPH SERIES


23

**Treating Smoking in
Cancer Patients:
An Essential
Component of
Cancer Care**



NCI's Smokefree.gov Initiative (SFGI)

- SFGI offers a suite of free **web- and mobile-based smoking cessation resources** that provide evidence-based information and support to people who use tobacco and want to quit (data and message rates may apply)
- Smokefree.gov resources reach **~7-8 million** people per year
- Active **partnerships** maintained with several Federal agencies: Centers for Disease Control and Prevention, Food and Drug Administration, Indian Health Service, and US Department of Veteran's Affairs
- Recent partner activities:
 - [National Text Portal](#) (launched March 2022)
 - SmokefreeTeen – [Next Legends](#) landing page (launching May 2022)




NCI Research Impacts on Policy

- Monograph 9 (Cigars: Health Effects and Trends) provided evidence used for FDA's proposed rule on flavors in cigars
- NCI funding ([Networks Among Tribal Organizations for Clean Air Policies \(NATO CAP\)](#)), laid the groundwork for the Navaho Nation's Air is Life Act of 2021, the first comprehensive ban on commercial tobacco products on American Indian tribal lands
- April 28, 2022, [FDA proposes rules prohibiting menthol cigarettes and flavored cigars](#): NCI-funded research helped build the science base



Alcohol Research Initiatives

Alcohol in comparison to other modifiable risk factors



Estimated Proportion and Number of Incident Cancer Cases Attributable to Evaluated Risk Factors in Adults Aged 30 Years and Older in the United States in 2014

Islami et al., 2018

Related Initiatives and Resources

December 13, 2019

Alcohol and Cancer Risk Clinical and Research Implications

William M. P. Klein, PhD¹; Paul B. Jacobsen, PhD²; Kathy J. Helzlsouer, MD, MHS³

[» Author Affiliations](#) | [Article Information](#)

JAMA. 2020;323(1):23-24. doi:10.1001/jama.2019.19133



Webinars

- Communication Approaches for Increasing Awareness of the Link Between Alcohol and Cancer (2022)
- Alcohol as a Target for Cancer Prevention and Control: Research Challenges (2020)
- Alcohol and Cancer in the United States (2018)

Alcohol and Cancer:
Identifying Evidence Gaps
and Research Challenges
Across the Cancer Continuum

December 8-10, 2020

This workshop brought together basic, epidemiologic, behavioral, translational, clinical, regulatory, and communication scientists to discuss evidence gaps related to the role of alcohol across the cancer continuum.

- [Meeting Agenda](#)
- [Public Webinar](#)
- [Meeting Executive Summary](#)
- [White Paper](#)

CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION | MINIREVIEW


Alcohol and Cancer: Existing Knowledge and Evidence Gaps across the Cancer Continuum

Susan M. Gapstur¹, Elisa V. Bandera², David H. Jernigan³, Noelle K. LoConte⁴, Brian G. Southwell⁵, Vasilis Vasiliou⁶, Abenaa M. Brewster⁷, Timothy S. Naimi⁸, Courtney L. Scherr⁹, and Kevin D. Shield¹⁰

Cannabis Research Initiatives

P30 Administrative Supplement Cancer Centers Awards and Cannabis Legalization Status Map

- Memorial Sloan Kettering Cancer Center: locations in NY and NJ
- Sidney Kimmel Cancer Center locations in PA, MD and NJ
- Abramson Cancer Center is in close proximity to NJ



* In early 2021, New York legalized marijuana for recreational use. However, since implementation lags, the legalization status change will not affect this survey.

Cannabis Research Symposium – Topics Covered


1. Non-medical Cannabis Use and Cancer Epidemiology
2. Cannabis and the Cancer Patient
3. Cancer Symptom/Treatment Side Effect Management – Preclinical
4. Cancer Symptom/Treatment Side Effect Management – Clinical
5. Cancer Biology and Prevention
6. Cancer Treatment – Pre-Clinical and Clinical
7. Navigating Research Challenges for Cannabis Research
8. Panel Discussion to Discuss Research Directions



<https://events.cancer.gov/nci/cannabisresearch/agenda>

Support research to assess potential benefits and harms of cannabis and cannabinoid use among cancer patients

- How and why cancer patients are currently using cannabis?
 - Mode, dosage, frequency, and product
- What are the potential benefits and harms of cannabis use among cancer patients associated with?
 - Cancer and its treatments
 - Comorbidities
 - Other medications (prescribed, complementary, and alternative medicines)



American Indian/Alaska Native (AI/AN)-Specific Initiatives

Intervention Research to Improve Native American Health (IRINAH)



- Initiated by NCI in 2011, now led by NIDA (starting in 2021)
- Program has 15 ICs participating, with FOA seeking applications for R01/R21
- Funded grantees have monthly meetings (which DCCPS coordinates) to maintain a network of researchers
- NIH staff currently updating the portfolio analysis
- NCI currently funded projects: 3 R01s (two focusing on CRC screening and prevention, one on lung cancer screening); 1 R21 (smoking cessation)

<https://cancercontrol.cancer.gov/nativeamericanintervention/>

CRC Screening Efforts in American Indian Communities

Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains and Southwest United States

- Cancer MoonshotSM supplement awards to three NCI Designated Cancer Centers (beginning in 2018)
- Parallel effort to **ACCSIS**: Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)
- Long-term goals:
 - Enhance health equity through the reduction of CRC disparities in morbidity, mortality, stage-at-diagnosis, and increased survival among AIs

University of Arizona:

Dr. Peter Lance and Dr. Jennifer Hatcher

University of New Mexico:

Dr. Shiraz Mishra and Dr. Kevin English

University of Oklahoma:

Dr. Mark Doescher

<https://cancercontrol.cancer.gov/hdhe/native-american-health/colorectal-cancer-screening-american-indian>

Funding


DCCPS Cancer Center Support Grants Supplements: History and A Look Ahead

From FY 2014 – FY 2021

- HPV Vaccination Uptake
- Catchment Area Analyses
- Tobacco Cessation
- Rural & AI/AN
- Aging
- Cannabis Use
- NCCR
- COE
- Financial Hardship
- Childhood Cancer Survivors
- Persistent Poverty

Planning for FY 2022 – FY 2023

- Advancing cancer screening in underserved communities with HRSA
- Research focusing on sexual and gender minority populations with CRCHD and NIH OD
- Continued coordination for the Moonshot cancer center cessation initiative



<https://cancercontrol.cancer.gov/research-emphasis/supplement>

Selected Active Funding Opportunities for Tobacco, Cannabis, Alcohol and Cancer Research

Title	Announcement #	Contact
Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer	NOT-CA-22-085	Ron Johnson rjohnso2@mail.nih.gov Sharon Ross rosssha@mail.nih.gov Yali Fu fuyali@mail.nih.gov Jeffrey White jeffreyw@mail.nih.gov
Notice of Special Interest (NOSI): Administrative Supplements for Examining Patterns of Tobacco and Cannabis Use	NOT-CA-22-070	Joseph Ciccolo ciccolojt@nih.gov
Notice of Special Interest (NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes	NOT-AA-21-028	Carolyn Reyes-Guzman Carolyn.reyes-guzman@nih.gov

Selected Active Funding Opportunities for Tobacco, Cannabis, Alcohol and Cancer Research

Title	Announcement #	Contact
Integrative Research on Polysubstance Abuse and Disorder	PAR-20-035	Annette Kaufman kaufmana@mail.nih.gov David Berrigan berrigad@nih.gov
Notice of Special Interest (NOSI): Alcohol and Cancer Control	NOT-CA-20-034	Tanya Agurs-Collins collinsta@nih.gov

Selected Past Funding Opportunities for Tobacco, Cannabis, Alcohol and Cancer Research

Title	Announcement #	Contact
Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects	NOT-OD-22-022	Ron Johnson rjohnso2@mail.nih.gov
Improving Smoking Cessation Interventions among People Living with HIV	RFA-CA-20-035 (R01 Clinical Trial Optional) and RFA-CA-20-036 (R21 Clinical Trial Optional)	Annette Kaufman kaufmana@mail.nih.gov

Data Collection

Data Collection

- **Health Information National Trends Survey**

- Variables of interest
 - Alcohol risk perceptions
 - Tobacco use and tobacco product risk perceptions
 - E-cigarette use and ENDS risk perceptions



- **Tobacco Use Supplement to the Current Population Survey (TUS-CPS)**

- Variables of interest
 - Tobacco use
 - E-cigarette use
 - Tobacco and marijuana co-use (for 2022-2023 questionnaire)



TUS-CPS Accomplishments

Preparing to field the 2022-2023 wave

- Revising questionnaire to remove outdated items and revise response items based on latest research and consumer data
- Introducing new questions on **nicotine pouches** and **marijuana and tobacco/nicotine co-use**

New Technical Assistance Resources for Users

- 4-part webinar series in 2021 focusing on newer users; consistent attendance of over 50 people per webinar
- Hand-on guides for users, including for weighted analysis and upcoming one on harmonized dataset

New linkage- the Tobacco Longitudinal Mortality Study (TLMS)

- Will allow research that explores long-term patterns of tobacco product use and associated morbidity/mortality (> 1 million records, 1993-2019)
- Will expand to include SEER registry data in future



Website:

<https://cancercontrol.cancer.gov/brp>

Twitter:

[@NCIBehaviors](#)

Newsletter:

<https://cancercontrol.cancer.gov/brpsubscribe>



William Klein, Ph.D.
Associate Director
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
kleinwm@mail.nih.gov



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol